1 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
2 Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–73.
3 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
4 El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385(19):1774–85.
5 Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. 2021;326(12):1210–2.
6 Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJM, Shekarriz-Foumani R, et al. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol. 2022;32(4):e2318.
7 Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a arge health care organization. N Engl J Med. 2021;385(23):2132–9.
8 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.
9 Ciancone D, Boehm R, Aragao A, Pazhenkottil AP. Perimyokarditis nach COVID-19-Impfung. Swiss Med Forum. 2022;22(39):652–54.
10 Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll of Cardiol. 2018;72(24):3158–76.
11 Fischer K, Obrist SJ, Erne SA, Stark AW, Marggraf M, Kaneko K, et al. Feature tracking myocardial strain incrementally improves prognostication in myocarditis beyond traditional CMR imaging features. JACC Cardiovasc Imaging. 2020;13(9):1891–901.
12 Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70(16):1964–76.
13 Eichhorn C, Greulich S, Bucciarelli-Ducci C, Sznitman R, Kwong RY, Gräni C. Multiparametric cardiovascular magnetic resonance approach in diagnosing, monitoring, and prognostication of myocarditis. JACC Cardiovasc Imaging. 2022;15(7):1325–38.
14 Fronza M, Thavendiranathan P, Chan V, Karur GR, Udell JA, Wald RM, et al. Myocardial injury pattern at MRI in COVID-19 vaccine-associated myocarditis. Radiology. 2022;304(3):553–62.
15 Patel YR, Shah NR, Lombardi K, Agarwal S, Has P, Patel R, et al. Cardiac MRI findings in male patients with acute myocarditis in the presence or absence of COVID-19 vaccination. Radiol Cardiothorac Imaging. 2022;4(3):e220008.
16 Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73.
17 Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical research in cardiology: Official journal of the German Cardiac Society 2020;109(5):531–8.
18 Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8.
19 Skarbinski J, Wood MS, Chervo TC, Schapiro JM, Elkin EP, Valice E, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. Lancet Reg Health Am. 2022;12:100297.
20 Schmied C, Noack P, Betschart HP, Carrard J, Clénin G, Gojanovic B, et al. Flowcharts – SARS-CoV-2 – Return to training and competition [Internet]. Bern: Sport & Excercise Medicine Switzerland; 2022 [abgerufen am 02.09.2022]. Verfügbar unter:
https://sems.ch/fileadmin/user_upload/Covid-19_Flow-Charts/SO_Flowcharts_A4_DE_270422.pdf
21 Boscolo Berto M, Spano G, Wagner B, Bernhard B, Häner J, Huber AT, Gräni C. Takotsubo cardiomyopathy after mRNA COVID-19 vaccination. Heart Lung Circ. 2021;30(12):e119–20.
22 Kawamura Y, Yoshimachi F, Nanao T, Kasai S, Ikari Y. A case of ST segment elevation myocardial infarction within 24 h of a third dose of COVID-19 mRNA vaccine. Cardiovasc Revasc Med. 2022;S1553-8389(22)00304-9.
23 Mishra A, Komut O, Kumar A, Ete T, Megeji RD. Acute myocardial infarction after COVID-19 vaccination: A case report. Cureus. 2022;14(5):e25536.
24 Stewart C, Gamble DT, Dawson D. Novel case of takotsubo cardiomyopathy following COVID-19 vaccination. BMJ Case Rep 2022;15(1):e247291.
25 Eichhorn C, Bière L, Schnell F, Schmied C, Wilhelm M, Kwong RY, et al. Myocarditis in athletes is a challenge: Diagnosis, risk stratification, and uncertainties. JACC Cardiovasc Imaging. 2020;13(2 Pt 1):494–507.
26 Gluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: Myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717–56.